# GOSS catalysts: Gossamer Bio, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/goss/catalysts

> Gossamer Bio, Inc. (GOSS) has 2 upcoming catalysts. The next is the seralutinib primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Gossamer Bio, Inc. |
| Ticker | GOSS (Nasdaq) |
| SEC CIK | 1728117 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/goss |

## Cash runway

Cash $51.2M as of 2026-09-30; quarterly burn $29.6M; about 5.2 months of runway at that rate (XBRL company facts, accession 0001728117-26-000114).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2022 | [Seralutinib topline data readout](https://sec-api.dev/pdufa/seralutinib) | GOSS |  | completed, positive | "In December 2022, we announced positive topline results from the Phase 2 TORREY Study in PAH patients." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000081/goss-20250930.htm)) |
| March 13, 2025 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000022/goss-20250313xexx991.htm)) |
| May 15, 2025 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000037/goss-20250515xexx991.htm)) |
| August 5, 2025 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000069/goss-20250805xexx991.htm)) |
| Q4 2025 | [Seralutinib topline data readout](https://sec-api.dev/pdufa/seralutinib) | GOSS |  | scheduled | "Topline results from the PROSERA Study are expected in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000022/goss-20250313xexx991.htm)) |
| Q4 2025 | [Gossamer Bio, Inc. topline data readout](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | scheduled | "We expect to report topline data from the PROSERA study in the fourth quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000021/goss-20241231.htm)) |
| November 5, 2025 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000082/goss-20251105xexx991.htm)) |
| Feb 2026 | [Seralutinib topline data readout](https://sec-api.dev/pdufa/seralutinib) | GOSS |  | completed, missed | "- Topline Results from PROSERA Phase 3 Expected in February 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000082/goss-20251105xexx991.htm)) |
| March 17, 2026 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000018/goss-20260317xexx991.htm)) |
| May 18, 2026 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000036/goss-20260518xexx991xearni.htm)) |
| Jun 2026 | [Seralutinib NDA/BLA submission](https://sec-api.dev/pdufa/seralutinib) | GOSS | PAH in September 2026 | completed | "Following a Pre-NDA Type B meeting with the FDA held in mid-June 2026 and receipt of the official meeting minutes, we submitted an NDA for seralutinib for the treatment of PAH in September 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000114/goss-20260930.htm)) |
| August 13, 2026 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000073/goss-20260813xexx991xearni.htm)) |
| September 9, 2026 | [Gb002 (seralutinib) primary completion](https://sec-api.dev/pdufa/gb002-seralutinib) | GOSS | Pulmonary Arterial Hypertension | withdrawn | "NCT04816604 (Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-09 (ACTUAL); Lead Sponsor Gossamer Bio USA, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04816604)) |
| September 23, 2026 | [Seralutinib NDA/BLA submission](https://sec-api.dev/pdufa/seralutinib) | GOSS | pulmonary arterial hypertension | completed | "On September 23, 2026, Gossamer Bio, Inc. (the "Company") announced that it submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension ("PAH")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000104/goss-20260923.htm)) |
| November 10, 2026 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000116/goss-20261110xexx991xearni.htm)) |
| December 2026 | [Seralutinib primary completion](https://sec-api.dev/pdufa/seralutinib) | GOSS | Pulmonary Arterial Hypertension | scheduled | "NCT06274801 (Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gossamer Bio USA, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06274801)) |
| Dec 2026 to Mar 2027 | [Seralutinib topline data readout](https://sec-api.dev/pdufa/seralutinib) | GOSS | Pulmonary Arterial Hypertension | scheduled | "NCT06274801 (Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gossamer Bio USA, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06274801)) |

## Drugs

- [Gb002 (seralutinib)](https://sec-api.dev/pdufa/gb002-seralutinib): Pulmonary Arterial Hypertension
- [Seralutinib](https://sec-api.dev/pdufa/seralutinib): pah in september 2026, pah based in part, pulmonary arterial hypertension, with pah in september 2026

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/goss/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GOSS catalysts: Gossamer Bio, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/goss/catalysts

```bibtex
@misc{secapidev_companies_goss_catalysts_20261116,
  title        = {GOSS catalysts: Gossamer Bio, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/goss/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_goss_catalysts_20261116","title":"GOSS catalysts: Gossamer Bio, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/goss/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
